Hengrui PD-L1 monoclonal antibody shr-1316 will enter clinical phase 3, and will be on the market soon
-
Last Update: 2018-12-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On December 4, Hengrui pharmaceutical announced that the company and its subsidiary Shanghai Hengrui pharmaceutical will carry out the phase III clinical trial of shr-1316 injection in the near future Shr-1316 injection is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui medicine, which is mainly used for the treatment of malignant tumors At present, similar products atezolizumab (trade name tecentriq ®), avelumab (trade name bavencio ®) and durvalumab (trade name imfinzi ®) have been approved for sale in the United States, but no similar products have been approved for sale in China Similar products hn035, cs1001 and kl-a167 are in clinical trial stage in China According to the announcement, the global sales volume of tecentriq ® in 2017 is about US $460 million, that of bavencio ® is about US $26 million, and that of imfinzi ® is about US $18 million The full text of the announcement is as follows:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
